Stoke Therapeutics, Inc. (NASDAQ:STOK – Get Free Report) insider Barry Ticho sold 6,686 shares of the company’s stock in a transaction on Wednesday, March 18th. The stock was sold at an average price of $31.34, for a total value of $209,539.24. Following the completion of the sale, the insider owned 40,798 shares of the company’s […]

Stoke Therapeutics, Inc. (NASDAQ:STOK – Get Free Report) insider Barry Ticho sold 1,461 shares of Stoke Therapeutics stock in a transaction dated Thursday, March 19th. The shares were sold at an average price of $29.99, for a total transaction of $43,815.39. Following the sale, the insider owned 40,702 shares of the company’s stock, valued at […]

Stoke Therapeutics, Inc. (NASDAQ:STOK – Get Free Report) insider Barry Ticho sold 6,164 shares of the company’s stock in a transaction that occurred on Tuesday, March 17th. The stock was sold at an average price of $33.01, for a total value of $203,473.64. Following the sale, the insider directly owned 47,484 shares of the company’s […]

Stoke Therapeutics, Inc. (NASDAQ:STOK – Get Free Report) insider Jason Hoitt sold 1,781 shares of the company’s stock in a transaction dated Tuesday, March 17th. The stock was sold at an average price of $33.01, for a total transaction of $58,790.81. Following the transaction, the insider owned 12,207 shares of the company’s stock, valued at […]

Esperion Therapeutics, Inc. (NASDAQ:ESPR – Get Free Report) CFO Benjamin Halladay sold 6,424 shares of the stock in a transaction dated Tuesday, March 17th. The shares were sold at an average price of $2.71, for a total value of $17,409.04. Following the transaction, the chief financial officer owned 713,602 shares in the company, valued at […]

Esperion Therapeutics, Inc. (NASDAQ:ESPR – Get Free Report) insider Benjamin Looker sold 5,708 shares of the firm’s stock in a transaction dated Tuesday, March 17th. The shares were sold at an average price of $2.70, for a total transaction of $15,411.60. Following the completion of the sale, the insider owned 679,348 shares in the company, […]

CRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report) insider Naimish Patel sold 3,150 shares of the business’s stock in a transaction dated Monday, March 16th. The shares were sold at an average price of $48.26, for a total transaction of $152,019.00. Following the completion of the transaction, the insider owned 13,143 shares in the company, […]